DongKook Pharmaceutical Co. Ltd (086450) - Total Assets
Based on the latest financial reports, DongKook Pharmaceutical Co. Ltd (086450) holds total assets worth ₩1.06 Trillion KRW (≈ $720.31 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of DongKook Pharmaceutical Co. Ltd for net asset value and shareholders' equity analysis.
DongKook Pharmaceutical Co. Ltd - Total Assets Trend (2013–2025)
This chart illustrates how DongKook Pharmaceutical Co. Ltd's total assets have evolved over time, based on quarterly financial data.
DongKook Pharmaceutical Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
DongKook Pharmaceutical Co. Ltd's total assets of ₩1.06 Trillion consist of 53.2% current assets and 46.8% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 5.3% |
| Accounts Receivable | ₩222.16 Billion | 20.9% |
| Inventory | ₩175.25 Billion | 16.5% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩30.05 Billion | 2.8% |
| Goodwill | ₩12.17 Billion | 1.2% |
Asset Composition Trend (2013–2025)
This chart illustrates how DongKook Pharmaceutical Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see DongKook Pharmaceutical Co. Ltd market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: DongKook Pharmaceutical Co. Ltd's current assets represent 53.2% of total assets in 2025, an increase from 0.0% in 2013.
- Cash Position: Cash and equivalents constituted 5.3% of total assets in 2025, down from 6.2% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 2.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 20.9% of total assets.
DongKook Pharmaceutical Co. Ltd Competitors by Total Assets
Key competitors of DongKook Pharmaceutical Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Theragen Etex Co.Ltd
KQ:066700
|
Korea | ₩245.25 Billion |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
|
Korea | ₩529.96 Billion |
|
ST Pharm Co.Ltd
KQ:237690
|
Korea | ₩782.57 Billion |
|
Oscotec Inc
KQ:039200
|
Korea | ₩154.14 Billion |
|
Caregen Co.Ltd
KQ:214370
|
Korea | ₩233.98 Billion |
|
NatureCell Co.Ltd
KQ:007390
|
Korea | ₩71.32 Billion |
|
Mezzion Pharma Co.Ltd
KQ:140410
|
Korea | ₩87.88 Billion |
|
Huons Global Co. Ltd
KQ:084110
|
Korea | ₩1.47 Trillion |
DongKook Pharmaceutical Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.11 | 2.02 | 2.60 |
| Quick Ratio | 1.46 | 1.33 | 2.04 |
| Cash Ratio | 0.00 | 0.22 | 0.00 |
| Working Capital | ₩297.98 Billion | ₩237.31 Billion | ₩252.49 Billion |
DongKook Pharmaceutical Co. Ltd - Advanced Valuation Insights
This section examines the relationship between DongKook Pharmaceutical Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.83 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 11.5% |
| Total Assets | ₩1.06 Trillion |
| Market Capitalization | $142.36 Million USD |
Valuation Analysis
Below Book Valuation: The market values DongKook Pharmaceutical Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: DongKook Pharmaceutical Co. Ltd's assets grew by 11.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for DongKook Pharmaceutical Co. Ltd (2013–2025)
The table below shows the annual total assets of DongKook Pharmaceutical Co. Ltd from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩1.06 Trillion ≈ $720.31 Million |
+11.51% |
| 2024-12-31 | ₩953.16 Billion ≈ $645.95 Million |
+13.53% |
| 2023-12-31 | ₩839.54 Billion ≈ $568.94 Million |
+9.27% |
| 2022-12-31 | ₩768.33 Billion ≈ $520.69 Million |
+2.43% |
| 2021-12-31 | ₩750.08 Billion ≈ $508.32 Million |
+13.11% |
| 2020-12-31 | ₩663.17 Billion ≈ $449.42 Million |
+21.82% |
| 2019-12-31 | ₩544.38 Billion ≈ $368.92 Million |
+13.36% |
| 2018-12-31 | ₩480.24 Billion ≈ $325.45 Million |
+28.65% |
| 2017-12-31 | ₩373.31 Billion ≈ $252.99 Million |
+14.83% |
| 2016-12-31 | ₩325.10 Billion ≈ $220.31 Million |
+18.30% |
| 2015-12-31 | ₩274.80 Billion ≈ $186.23 Million |
+12.55% |
| 2014-12-31 | ₩244.17 Billion ≈ $165.47 Million |
+11.87% |
| 2013-12-31 | ₩218.26 Billion ≈ $147.91 Million |
-- |
About DongKook Pharmaceutical Co. Ltd
DongKook Pharmaceutical Co., Ltd. provides pharmaceutical products in South Korea and internationally. It produces active pharmaceutical ingredients, including propofol, streptokinase, and teicoplanin; disposable syringes; and pills, capsules, and ointments, as well as small volume parentral, large volume parentral, and lyophilized injectable drug injections. The company also offers Teicon, Durak… Read more